Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs Ross Stores, Inc. (ROST) Price & Performance

Moderna, Inc.Trade
Ross Stores, Inc.Trade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Ross Stores, Inc. — how do they compare? Moderna, Inc. trades at $64.06 (market cap $24.18B), while Ross Stores, Inc. trades at $248.14 (market cap $80.78B). The key difference: Ross Stores, Inc. is far larger — about 3.3× Moderna, Inc.'s market cap, and Ross Stores, Inc. pays a 0.71% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

MRNAROST
Market Cap
$24.18B$80.78B
Sector
HealthConsumer Cyclical
52-Week High
$81.80$255.23
52-Week Low
$22.36$144.67
Enterprise Value
$20.33B$81.37B
Dividend Yield
0.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Ross Stores, Inc.

ROST trades at $250.45, down 1.72% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $259.00. The company has consistently beaten earnings estimates, with Q1 2026 EPS of $2.02 exceeding the $1.73 forecast. Strong fundamentals include a net income margin of 9.74% and ROE of 38.98%, supported by revenue growth to $21.13 billion in 2025 and recent expansion with 47 new stores opened in mid-2026.

The outlook remains positive given earnings momentum and store growth, but elevated valuation ratios like a P/E of 35.17 pose a risk if growth slows. Analyst sentiment is bullish with 64% buy ratings, though technical indicators show mixed signals with RSI near overbought levels. Investors should weigh robust profitability against high multiples in a competitive retail sector.

Returns comparison

Trailing returns across standard periods

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About Ross Stores, Inc.

Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach

Read more on ROST